U.S. equities finished mostly higher on Wednesday, August 12, 2026, after July inflation data came in broadly in line with expectations. The Nasdaq Composite and Russell 2000 outperformed, the S&P 500 ended modestly higher, and the Dow Jones Industrial Average finished slightly lower. Investor risk appetite improved as the VIX declined sharply, while gold continued to advance.

August 12 market performance

Index or asset	Close	Daily change
S&P 500	7,748.50	+20.30, +0.26%
Dow Jones Industrial Average	53,770.27	-21.58, -0.04%
Nasdaq Composite	26,588.49	+143.04, +0.54%
Russell 2000	3,045.76	+18.64, +0.62%
CBOE Volatility Index	14.44	-0.84, -5.50%
Gold futures	$4,473.00	+$31.90, +0.72%

The market’s internals favored growth and smaller-capitalization companies: the Nasdaq rose 0.54% and the Russell 2000 gained 0.62%, while the blue-chip Dow slipped 0.04%. The decline in the CBOE Volatility Index to 14.44 signaled reduced near-term demand for equity hedges. Gold’s 0.72% gain, however, showed that inflation, geopolitical, and policy uncertainty remain part of the investment backdrop,

CPI report supports risk appetite

The Bureau of Labor Statistics reported that the July Consumer Price Index increased 0.1% month over month and 3.4% from a year earlier, easing from June’s 3.5% annual pace. Core CPI, which excludes food and energy, increased 0.2% for the month and 2.5% year over year, down from 2.6% in June. The details were constructive but not an all-clear signal for policymakers. Shelter rose 0.1% and accounted for roughly two-thirds of the monthly headline increase, while the energy index fell 1.5% and gasoline declined 2.9% in July. Medical care services rose 0.6%, airline fares climbed 2.2%, and core services inflation remains relevant to the Federal Reserve’s policy outlook.

Macroeconomic commentary: The report gave equity investors a reason to add risk because it did not materially intensify the inflation narrative ahead of the Federal Reserve’s September meeting. Still, annual headline CPI at 3.4% and core CPI at 2.5% remain above the Fed’s 2% inflation objective. The market’s favorable reaction should therefore be read as relief that inflation did not surprise to the upside—not necessarily as confirmation of an imminent policy pivot. The next market test arrives with the July Producer Price Index report on Thursday. Investors will be watching whether producer-level inflation corroborates the cooler consumer-price trend and whether bond yields remain contained.

AI leadership: CoreWeave earnings

CoreWeave (CRWV) was a focal point in the AI infrastructure trade after reporting second-quarter revenue of $2.6 billion, up 112% from $1.2 billion a year earlier. The company guided for third-quarter revenue of $3.4 billion to $3.6 billion and said its revenue backlog stood at $104 billion as of June 30, excluding $25 billion in new third-quarter commitments. Shares of CoreWeave (CRWV) climbed roughly 19.8% on August 12, closing near $108.18 after trading as high as $111.64 during the session. The company’s results reinforced the market’s conviction that demand for accelerated computing capacity remains strong, helped by expanding enterprise AI adoption and large customer commitments, including an additional $21 billion commitment from Meta Platforms (META). The important caveat is profitability and capital intensity. CoreWeave (CRWV) reported operating expenses of $2.6 billion and an operating loss of $49 million for the quarter. Its investment case continues to rest on whether rapid revenue growth, pricing strength, and backlog conversion can outpace the cost and debt burden of building AI cloud infrastructure.

What investors are watching

Producer inflation: Thursday’s PPI report will help determine whether July’s benign CPI reading reflects broader disinflation or primarily lower energy prices.
Federal Reserve expectations: Markets will reassess the probability of a September policy move as CPI, PPI, labor-market data, and Treasury yields evolve.
AI earnings follow-through: CoreWeave (CRWV) illustrates continued demand for AI compute, but investors will remain focused on margins, leverage, customer concentration, and execution.
Market breadth: The Russell 2000’s relative strength is encouraging, but sustained rotation beyond mega-cap technology will be necessary for a more durable broad-market advance.
Gold and volatility: A rising gold price alongside a falling VIX suggests investors are participating in risk assets while keeping longer-term macro and geopolitical hedges in place.

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $12.65. Amwell® (NYSE: AMWL) announced (Aug. 4) financial results for the second quarter ended June 30, 2026. Dr. Ido Schoenberg, Chairman and CEO of Amwell stated, “The DHA’s intent to make Amwell a prime contractor is a powerful endorsement of our platform and our people. With subscription revenue now approaching half our total revenue, independently validated behavioral clinical outcomes, no debt, and positive cash flows from operations projected for the fourth quarter this year, we have never been better positioned to lead the era of AI-powered care.”

Amwell Second Quarter 2026 Highlights:

Recorded Total Revenue of $52.0 million at the top end of the previously provided financial guidance range for Q2
- Achieved subscription revenue of $25.7 million
- Recorded Amwell Medical Group (“AMG”) visit revenue of $24.4 million
Reported gross margin of 53%
Net loss was ($9.6) million, compared to ($10.3) million in the first quarter of 2026, continuously moving from quarter to quarter in a favorable trajectory
Adjusted EBITDA of ($1.2) million compared to ($3.1) million in the first quarter of 2026
Total visits on the platform were 0.8 million.

Financial Outlook

The Company is significantly improving Adjusted EBITDA, reaffirming its AMG visit guidance, and raising the low end of its 2026 revenue outlook:

Revenue in the range of $200 million to $205 million increased from $195 million to $205 million
AMG visits between 1.32 million and 1.37 million
Adjusted EBITDA in the range between ($9) million to ($7) million increased from ($16) million to ($12) million.

The Company also provided financial guidance for Q3 2026 Revenue and adjusted EBITDA:

Q3 revenue in the range of $46 million to $48 million
Q3 adjusted EBITDA expected to in the range of ($5) million to ($3) million.

The Company also reiterated its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Hudson Pacific Properties (NYSE: HPP)

Hudson Pacific Properties (NYSE: HPP, $14.31, +7.19%) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space. HPP turned in a quarter ( Aug. 5) that suggests the office malaise is not over, but it may finally be meeting resistance. Revenue came in above Wall Street’s expectations, occupancy moved higher for a fourth straight quarter, and management raised full-year guidance — a combination that does not make for a triumphant victory lap, but it does make for a more credible turnaround narrative. Learn more.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.48), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, wrapped up its KOL event today with a clear message for Wall Street and the GI community: EP‑104GI is not just another esophageal steroid, it is being architected to live comfortably inside real‑world upper endoscopy practice for eosinophilic esophagitis (EoE) patients. By the end of the session, the tone had shifted from “could this work?” to “this is how we would use it on Monday,” which is exactly the inflection investors watch for

EPRX announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”

Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $2.07, +2.73%), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, announced (Aug. 5) that management will host a booth at the Association of Diabetes Care & Education Specialists 2026 Annual Conference (the “Conference”) in Columbus, Ohio, from August 7-10, 2026, where they will showcase the new Pivot tubeless insulin patch pump.

MODD announced (Aug. 3) plans to initiate the first phase of commercialization of its Pivot tubeless patch pump across five strategically selected U.S. markets beginning in October 2026. The initial rollout will include Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia, representing a foundational step in the Company’s capital efficient commercialization strategy with its mission to expand access to simplified insulin delivery solutions for all people living with diabetes.

MODD recently (July 22) announced the formation of its Pivot Innovation Council, a cross-functional group of leading clinicians and healthcare experts established to help guide the company’s clinical and commercial strategy. Diabetes care expert Robert Gabbay, MD, PhD, FACP was appointed as chair of the Pivot Innovation Council. The council will provide insights on target patient populations, support optimization of clinical workflows, inform evidence-generation initiatives, and help refine the Pivot product roadmap and go-to-market approach, as the Company continues to scale its differentiated offering.

Modular released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.

Modular Medical (June 30) announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

Similarweb Ltd. (NYSE: SMWB)

Similarweb Ltd. (NYSE: SMWB) delivered the sort of second-quarter report investors tend to enjoy: revenue and profitability exceeded guidance, full-year expectations moved higher, and AI demand translated into contracts rather than merely conference-call poetry. On Wednesday, August 12, SMWB shares climbed roughly 17% in premarket trading after the release; during the regular session, the stock closed at $8.79, up $1.54, or 21.24%, up from the prior close of $7.25. Learn More.

LG Display Co., Ltd. (LPL)

LG Display Co., Ltd. (NYSE: LPL, 3.46, +.87%) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

Yatsen Group (NYSE: YSG)

Yatsen Group (NYSE: YSG, $3.36, .60%), a world-class beauty innovation pioneer, announced (July 8) a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership integrates Yatsen’s rigorous scientific infrastructure with the world’s leading prestige beauty retailer, marking a significant milestone in Yatsen’s continuing evolution into a global beauty technology powerhouse.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $24.99) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

Doximity, Inc. (NYSE: DOCS) announced (Aug. 6) results of its fiscal 2027 first quarter ended June 30, 2026. Jeff Tangney, co-founder and CEO of Doximity, “We’re proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement. In Q1 we had accelerated revenue growth along with workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter.”

Fiscal 2027 First Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended June 30, 2025.

Revenue: Revenue of $156.6 million, versus $145.9 million, an increase of 7% year-over-year.
Net income and non-GAAP net income: Net income of $24.3 million, versus $53.3 million, representing a margin of 15.5%, versus 36.5%. Non-GAAP net income of $55.0 million, versus $71.9 million, representing a margin of 35.1%, versus 49.2%.
Adjusted EBITDA: Adjusted EBITDA of $74.8 million, versus $79.8 million, a decrease of 6% year-over-year, representing adjusted EBITDA margins of 47.7%, versus 54.7%.
Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.13, versus $0.27, while non-GAAP diluted net income per share was $0.29, versus $0.36.
Operating cash flow and free cash flow: Operating cash flow of $42.0 million, versus $62.1 million, a decrease of 32% year-over-year, and free cash flow of $39.6 million, versus $60.1 million, a decrease of 34% year-over-year.

Financial Outlook

Doximity is providing guidance for its fiscal second quarter ending September 30, 2026 as follows:

Revenue between $170 million and $171 million.
Adjusted EBITDA between $80.5 million and $81.5 million.

Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows:

Revenue between $671 million and $681 million.
Adjusted EBITDA between $309 million and $329 million.

Sable Offshore Corp. (SOC)

Sable Offshore Corp. (NYSE: SOC, $4.38) has moved from the awkward “pre-revenue restoration project” phase into something much more recognizable to Wall Street: a company selling meaningful volumes of oil, generating operating cash flow, and building momentum into a potentially larger 2027 earnings base. The second-quarter report on Monday was not a polished victory lap—midstream bottlenecks and one-time costs made sure of that—but it offered something potentially more valuable: proof that the Santa Ynez Unit restart is translating into barrels, revenue, and operational traction. Learn more.

FMC (NYSE:FMC)

FMC Corporation is doing what smart industrial companies often do when the old playbook stops earning its keep: it is pruning, refocusing and leaning harder into the parts of the business that can actually grow. The result is not a victory lap, but it is starting to look like a cleaner, more investable story for FMC Corporation is doing what smart industrial companies often do when the old playbook stops earning its keep: it is pruning, refocusing and leaning harder into the parts of the business that can actually grow. The result is not a victory lap, but it is starting to look like a cleaner, more investable story for FMC [NYSE:FMC, $10.24].

T1 Energy Inc. (NYSE: TE)

T1 Energy Inc. (NYSE: TE, $4.90) offers a different type of growth story: one rooted in domestic production, trade-policy tailwinds and execution on solar manufacturing capacity. T1 reported second-quarter net sales of $250.1 million, produced 935 megawatts of solar modules at its G1_Dallas facility and generated adjusted EBITDA of $10.7 million. The company also monetized $39.1 million of 2025 Section 45X tax credits and ended the quarter with $156.4 million in cash, cash equivalents and restricted cash, including $79.1 million unrestricted. The headline loss should not be ignored: T1 reported a $36.9 million net loss from continuing operations, while its adjusted EBITDA benefited from $24.4 million in tariff refunds recognized in cost of sales. Yet the more interesting investor question is whether the company is creating a viable U.S. solar-manufacturing platform at a time when supply-chain security and domestic energy capacity carry unusually high strategic value. The company expects its first solar cells from a planned 2.1-gigawatt manufacturing facility in the first quarter of 2027. With 3 gigawatts of firm contracts, a 641-megawatt offtake agreement with Clearway and 2026 output expected toward the upper end of its 3.1-to-4.2-gigawatt range, T1’s story is increasingly about turning production capacity into contracted revenue. For investors, TE is less a conventional earnings multiple story than an execution-and-optionality story. If domestic solar demand remains durable and manufacturing milestones stay on schedule, the market may ultimately value the company less like a troubled commodity producer and more like a strategically positioned industrial platform.

Nvidia (NVDA, $224.09, +3.03%)

NVDA continues to expand its influence in AI with the launch of the Alpamayo model and a new $2 billion investment in AI infrastructure.

The Sources

This commentary is for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security.

Aug. 12, 2026 | Stock Market Today: Nasdaq and Small Caps Rise as July CPI Cools -( $CRWV $HPP $LPL $MODD $NVDA $SMWB Rise!)

You May Also Like

From “Soft Landing” to “Soft Thud”: What February Jobs Say Before the Fed Meets -( $DIA $QQQ $SPY $VIX )

Santa Rally in Gear: S&P 500, Dow, Nasdaq Climb as Small Caps, Gold, Silver Lead the Holiday Charge – December 22, 2025 -( $EPRX $GOOG $GOVX $LLY $MU $NVDA $ORCL $RIO $SOAR $RKLB $TSLA Rise!)

Your Guide To Staying Informed In The Markets